Precipio, Inc. PRPO 深 沪
等待开盘 05-19 09:30:00 美东时间
24.945
-1.095
-4.21%
华盛通- 最 高26.70
- 今 开25.52
- 成交量 4.91万股
- 最 低 24.73
- 昨 收 26.04
- 总市值 4458.60万
- 52周最高 33.63
- 市盈率 静 --
- 换手率 2.75%
- 52周最低 9.00
- 委 比 -16.62%
- 总股本 178.74万
- 历史最高 8448.00
- 量 比 1.46
- 振 幅 7.57%
- 历史最低 3.90
- 每 手 1
- 风险率 5.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Precipio Q1 EPS $(0.81) Down From $(0.59) YoY, Sales $6.711M Up From $4.929M YoY
Precipio (NASDAQ:PRPO) reported quarterly losses of $(0.81) per share. This is a 37.29 percent decrease over losses of $(0.59) per share from the same period last year. The company reported $6.711 million in sales this
05-15 05:03
Precipio Announces Q1 2026 Financial Results
Precipio, Inc. reported first-quarter 2026 revenue of $6.71M, flat from Q4-2025 but up 36% year-over-year. Product revenue declined temporarily due to delayed shipments. Adjusted EBITDA was $(0.16)M, impacted by CMS cuts, product shipment delays, and hiring costs. Cash flow was positive $60K. CEO Ilan Danieli noted underlying growth, particularly in the expanding product pipeline, expecting second-half growth.
05-14 21:00
Management team’s 2025 market-based Options have vested
Precipio, Inc. announced that its 2025 employee stock options granted to management vested due to a 400% increase in its share price from $6.06 to a 10-day VWAP of $30.30. The Company replaced standard time-based vesting with a market-based structure, where options vest upon reaching a specified share price. CEO Ilan Danieli highlighted this as aligning management incentives with shareholders. In 2026, management agreed to a similar structure wit...
05-13 21:00
Precipio Announces Q1-2026 Shareholder Update Call
Precipio, Inc. (NASDAQ: PRPO) will host its Q1-2026 shareholder update call on May 18, 2026, at 5:00 PM ET. The call will feature remarks on the company’s core businesses and include a live Q&A session. This is the first time Precipio will incorporate a dedicated moderated Q&A into its quarterly update. Investors can submit questions in advance to investors@precipiodx.com or join the call by dialing 646.307.1865. A replay will be available on Pre...
05-06 21:00
Earnings Scheduled For April 2, 2026
Companies Reporting Before The Bell • Pharvaris (NASDAQ:PHVS) is estimated to r...
04-02 19:11
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
Precipio, Inc., a specialty cancer diagnostics company, will host a conference call on April 2nd, 2026, at 5:00 PM ET to discuss Q4 and year-end 2025 updates. Participants can join by dialing 646.307.1865 and requesting the Precipio Inc. conference call. Pre-submitted questions can be emailed to investors@precipiodx.com. A replay will be available via Precipio's Investor page within 24 hours. Precipio focuses on improving cancer diagnostics to re...
03-12 21:00
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
Precipio, Inc. has launched the first and only BCR::ABL1 assay that simultaneously detects and quantifies all four clinically relevant isoforms, setting a new standard for monitoring Chronic Myeloid Leukemia (CML). Unlike existing assays, Precipio’s Bloodhound BCR::ABL1 assay provides full quantification of all four isoforms, enabling comprehensive disease monitoring and early detection of relapse. With high sensitivity, it detects changes as low...
03-10 13:00
Precipio Q4 2025 Preliminary Revenue $6.7M, An Increase Of 23% From $5.4M YoY
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025.Below are some of the key financial performance metrics
02-25 22:33
Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
Illustrating strong financial performance in 2025, Precipio Inc. reported a 30% YoY revenue increase from $18.5M to $24.0M, with Q4-2025 revenue at $6.7M (23% YoY growth). Adjusted EBITDA turned positive, reaching $0.95M in Q4 and $1.23M for the year, up from losses in 2024. The company also achieved $368K positive operating cash flow in Q4 and $688K annually, reflecting improved financial stability. CEO Ilan Danieli highlighted the importance of...
02-25 14:30
Precipio Takes Major Steps Toward a Clean Balance Sheet
Specialty cancer diagnostics company Precipio, Inc. has cleaned up its balance sheet with two major achievements: repaying a $1.1 million advance from Change Healthcare and exercising all financial warrants. The company now only holds a minor $80,000 loan and 10,000 warrants for vendors. CEO Ilan Danieli highlights reduced financial risk and ongoing efforts to grow the business and create shareholder value.
01-15 14:00
